Oncology Brothers (@OncBrothers) ranks #4 among US lung cancer KOLs, #4 among US breast cancer KOLs, #3 among US gi cancer KOLs, #3 among US gu cancer KOLs on X in 2026, by engagement from fellow physicians. 143 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: HERIZON-GEA-01, RASolute 302, PROTEUS. CMS Open Payments lists $12,280 in 2025 general payments.
At a Glance
- 84 posts naming a trial in 2026
- 65 trials discussed by name
- Lung Cancer: US #4, Global #6 · 83 physicians engaged
- Breast Cancer: US #4, Global #5 · 143 physicians engaged
- GI Cancer: US #3, Global #5 · 97 physicians engaged
- GU Cancer: US #3, Global #4 · 120 physicians engaged
- Leading physician voice: #1 of 74 physicians on HARMONi-6; #1 of 73 physicians on RASolute 302
- CMS Open Payments lists $12,280 in 2025 general payments.
This Month
What Oncology Brothers has posted in the last 30 days. Updated November 10, 2026.
Talazoparib now @FDA ✅ based off TALAPRO-3: Enzalutamide + Talazoparib vs. Enza alone in HRR mutated mCSPC: - At 3yrs, rPFS: 76.6% vs. 56.2% (HR: 0.48) - rPFS in BRCAm: 77.2% vs. 48.8% (HR: 0.37) - rPFS in nonBRCA: 76.2% vs. 60.2% (HR: 0.57) #OncTwitter #gusm #ProstateCancer https://t.co/RBNfJVW1iN
Day 3 (Presidential II) #ESMO26 highlights: 1. Krascendo-1: Divarasib in KRAS G12C NSCLC 2. SAFFRON: Osi + Savolitinib in EGFRm/MET+ NSCLC 3. CLARITY-Gastric01: Sone-Ve CLDN18.2 ADC in Gastric 4. HARMONi-GI1: Ivo + Chemo in 1L BTC 1/5 #OncTwitter #lcsm #gism @myESMO https://t.co/HCh0uT89j7
1. Krascendo-1: PhIII Divarasib vs sotorasib/adagrasib in prev-treated KRAS G12C NSCLC (n=338): - mPFS 9.8 vs 5.7mos (HR 0.58) - mOS 17.7 vs 12.0 mos (HR 0.56) - ORR 58% vs 32% - Fewer G3-4 TRAEs & discontinuations - New preferred G12C option? 2/5 https://t.co/nuJvJWTBOA https://t.co/WrHa6iRPjD
3. CLARITY-Gastric01: PhIII Sonesitatug vedotin (CLDN18.2 ADC) vs Chemo in 2L+ CLDN18.2+ Gastric/GEJ - 3L+ mOS 10.0 vs 5.0mos (HR 0.47) - 2L+ mOS 10.6 vs 6.4 mos (HR 0.58) - PFS not significant 🤔 - ADC activity even at lower CLDN18.2 expression 4/5 https://t.co/hNFhJsi6M6 https://t.co/dRhWgUE9cA
2. SAFFRON: PhIII Osimertinib + savolitinib vs plat-pem in EGFRm/MET-high NSCLC post-osi (n=338): - mPFS 7.6 vs 5.4mos (HR 0.55) - mOS 17.8 vs 12.9mos (HR 0.68) - All-oral, OS benefit in MET-driven resistance after Osi. 3/5 https://t.co/Ei5hi7Ma1F https://t.co/icpX7OvjgA
4. HARMONi-GI1: PhIII, Ivonescimab + gem/cis vs durva + gem/cis in 1L advanced BTC (n=682 🇨🇳 only study): - mOS 14.9 vs 12.1mos (HR 0.75) - mPFS 8.4 vs 5.8mos (HR 0.61) - ORR 54% vs 33% *Global confirmation needed… but we’ll likely see Ivo/PD1-VEGFi in our practice soon* 5/5 https://t.co/FBnWx8ahKl https://t.co/4lva04uqlh
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Oncology Brothers
Physicians who reposted Oncology Brothers’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #4 | #6 | 83 | 134 | Full ranking |
| Breast Cancer | #4 | #5 | 143 | 259 | Full ranking |
| GI Cancer | #3 | #5 | 97 | 166 | |
| GU Cancer | #3 | #4 | 120 | 208 |
What Colleagues Are Saying About Oncology Brothers
2026 posts by fellow physicians that mention @OncBrothers, quoted word for word.
#ESMO26 Abstracts Are Out! In our meta-analysis with the @OncBrothers (Rohit and Rahul), we compared first-line BRAF/MEK inhibitors with ICI-based regimens in BRAF V600E-mutant aNSCLC. Among 589 patients, BRAF/MEKis achieved higher response rates (61% vs 48%), with no differences in PFS or OS👇
Thanks @OncBrothers for putting together such a comprehensive panel, that covers the bread and butter of Community Oncology- Thoracic/ GU/ Breast/ GI, at the #ASCO26 As a Community onc myself, I need to continue to update myself on “all cancer types” and this seems like a “must go” session. I will also add, that most global oncologists would benefit from a session like this that covers the heart and soul of oncology. May 30, 6:30-9:00 PM CST. Thanks much, can’t wait! 🎀🙏 @NarjustFlorezMD @StephenVLiu @RManochakian @apolo_andrea @montypal @TiansterZhang @jhaveri_komal @hoperugo @GIcancerDoc @CathyEngMD @rachnatshroff @curijoey @healthpolicycop @ASCO @oncologyCOA @dapattmd @BarbaraMcAneny @yuan_ruiling @oncology101_org @IMG_Oncologists @HemOncFellows @HemOncWomenDocs @steveleeyc @aboutKP
Pre #esmo26 poll 🙂 Which one of the following trial will get standing ovation during esmo 2026 @myESMO What u think? @dr_yakupergun @OncBrothers . Any other trial ? Put it in comments 🙂 @KolPulseAI
Many thanks to the @OncBrothers for allowing me to be a part of yet another terrific program at #ASCO26! Was thrilled to see my @cityofhope colleague @hoperugo after my panel w @TiansterZhang & @apolo_andrea. Bonus: Got to see the incredible @jhaveri_komal just before she graced the stage!
Fantastic event w/ @OncBrothers summarizing the major updates from #ASCO26! 🩺🔥 Brilliant insights from an all-star panel on #lungcancer featuring @StephenVLiu, @NarjustFlorezMD, & @RManochakian. Caught up w/ @RManochakian to discuss exciting progress in small cell lung cancer! https://t.co/xYCnaDnsBS
Looking forward to joining the @OncBrothers & dear friends @apolo_andrea @montypal for this #ASCO26 adjacent discussion on Sat evening! https://t.co/DxLNicgAfJ
Trials Oncology Brothers Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| HERIZON-GEA-01 | 7 | #1 of 34 | Oct 23, 2026 |
| RASolute 302 | 7 | #1 of 73 | Oct 23, 2026 |
| PROTEUS | 6 | #4 of 56 | Oct 24, 2026 |
| ASCENT03 | 5 | #1 of 19 | Jul 4, 2026 |
| VOLGA | 4 | #4 of 57 | Oct 24, 2026 |
| TALAPRO-3 | 3 | #2 of 39 | Oct 26, 2026 |
| CLARITY-Gastric01 (CG-01) | 3 | #1 of 26 | Oct 25, 2026 |
| SAFFRON | 3 | #1 of 50 | Oct 25, 2026 |
| TROPION-Breast02 | 3 | #1 of 26 | Oct 24, 2026 |
| VIKTORIA-1 | 3 | #1 of 23 | Oct 24, 2026 |
| DASL-HiCaP (ANZUP1801) | 3 | #4 of 28 | Oct 24, 2026 |
| DeLLphi-305 | 3 | #4 of 86 | Oct 24, 2026 |
| LITESPARK-011 | 3 | #2 of 37 | Oct 9, 2026 |
| HARMONi-6 | 3 | #1 of 74 | May 31, 2026 |
| LIBRETTO-432 | 3 | #2 of 53 | May 31, 2026 |
| EV302 | 3 | #1 of 19 | May 29, 2026 |
| HARMONi-GI1 (AK112-309) | 2 | #3 of 26 | Oct 25, 2026 |
| KRASCENDO-1 | 2 | #5 of 49 | Oct 25, 2026 |
| CHECKMATE8HW | 2 | #3 of 9 | Oct 24, 2026 |
| postMONARCH | 2 | #1 of 18 | Oct 24, 2026 |
| DESTINY-Lung04 | 2 | #18 of 37 | Oct 24, 2026 |
| HORIZON-Breast06 | 2 | #2 of 15 | Oct 23, 2026 |
| NATALEE | 2 | #6 of 46 | Oct 23, 2026 |
| PEACE1 | 2 | #3 of 18 | Oct 23, 2026 |
| TALENT (TRIO-US B-12) | 2 | #2 of 23 | Oct 23, 2026 |
| ARROS-1 | 2 | #17 of 26 | Sep 15, 2026 |
| OPTIMA (UK) | 2 | #1 of 24 | Aug 5, 2026 |
| KEYNOTE-B15 / EV-304 | 2 | #4 of 44 | Jul 10, 2026 |
| PATINA | 2 | #1 of 21 | Jun 24, 2026 |
| lidERA | 2 | #1 of 23 | May 30, 2026 |
| CROWN | 2 | #2 of 36 | May 29, 2026 |
| DESTINY-Breast11 | 2 | #3 of 11 | May 15, 2026 |
| KEYNOTE-866 | 1 | #21 of 26 | Oct 23, 2026 |
| AZUR-1 | 1 | #2 of 14 | Oct 19, 2026 |
| ATOMIC | 1 | #1 of 9 | Oct 8, 2026 |
| HER2CLIMB-05 | 1 | #1 of 19 | Oct 7, 2026 |
| REFOCUS | 1 | #2 of 6 | Sep 23, 2026 |
| HARMONi | 1 | #6 of 16 | Sep 15, 2026 |
| ADAURA | 1 | #31 of 41 | Sep 15, 2026 |
| MAVERICK (SWOG S1827) | 1 | #23 of 33 | Sep 15, 2026 |
| PAPILLON | 1 | #24 of 26 | Sep 15, 2026 |
| SOHO-01 | 1 | #8 of 8 | Sep 9, 2026 |
| SERENA-6 | 1 | #11 of 39 | Sep 4, 2026 |
| PSMADDITION | 1 | #11 of 13 | Jul 31, 2026 |
| ASCENT-04 | 1 | #1 of 24 | Jun 24, 2026 |
| LITESPARK-022 | 1 | #3 of 40 | Jun 12, 2026 |
| CIRCULATE | 1 | #1 of 5 | Jun 2, 2026 |
| DeLLphi-304 | 1 | #4 of 23 | Jun 2, 2026 |
| EMERALD3 | 1 | #3 of 18 | Jun 2, 2026 |
| EVERA | 1 | #3 of 30 | Jun 2, 2026 |
| KEYNOTE-522 | 1 | #9 of 11 | May 30, 2026 |
| OptiTROP-Lung05 | 1 | #1 of 19 | May 29, 2026 |
| WU-KONG28 | 1 | #1 of 29 | May 29, 2026 |
| POTOMAC | 1 | #3 of 17 | May 28, 2026 |
| DESTINYBreast-05 | 1 | #2 of 11 | May 15, 2026 |
| persevERA | 1 | #1 of 12 | May 10, 2026 |
| VERITAC-2 (vepdegestrant) | 1 | #1 of 18 | May 1, 2026 |
| VERITAC-2 | 1 | #1 of 10 | May 1, 2026 |
| CAPITELLO281 | 1 | #7 of 21 | Mar 12, 2026 |
| CREST | 1 | — | Mar 12, 2026 |
| ILUSTRO | 1 | #11 of 11 | Jan 11, 2026 |
| BREAKWATER | 1 | #12 of 22 | Jan 11, 2026 |
| COMMIT | 1 | #9 of 14 | Jan 11, 2026 |
| KEYNOTE-937 | 1 | #10 of 12 | Jan 11, 2026 |
| GALAXY | 1 | #4 of 4 | Jan 11, 2026 |
Oncology Brothers on HERIZON-GEA-01
Day 1 #ESMO26 highlights Breast Ca 1. #NATALEE (update): Ribo Adj HR+ 2. #HorizonBreast06: ADCs in mBC 3. #TALENT: NeoAdj TDXd HR+ GI 4. #RASolute302: Panc Ca 5. #HerizonGEA01: GEJ/Gastric GU 6. #KN866: NeoAdj Pembro MIBC 7. #PEACE1: Abi in mHSPC #OncTwitter @myESMO 1/8 https://t.co/pkQxyvyRrG
5. HERIZON-GEA-01: Zanidatamab ± tislelizumab + chemo vs trastuzumab + chemo in 1L HER2+ advanced Gastric/GEJ - Zani + chemo: mOS 22.9 vs 19.6 mo (HR 0.76; p=0.0088) - Zani + TIS + chemo: mOS 27.0 vs 19.6 mo (HR 0.65); ~40% alive at 3 yrs - SoC for HER2+ in 1L 6/8 https://t.co/QpVwE1SbWF https://t.co/7cLJhcxVin
Zanidatamab + Chemo ± Tislelizumab is now the new SoC for Her2+ GEA based off HERIZON-GEA-01. Here we discussed this trial, findings, & AEs w/ @NataliyaUboha Full 🗣️ ⭐️ https://t.co/auFIASeOU4 ⭐️Also on “Oncology Brothers” podcast @OncUpdates #OncTwitter @OncoAlert https://t.co/kvtLnJmD7G
Oncology Brothers on RASolute 302
Day 1 #ESMO26 highlights Breast Ca 1. #NATALEE (update): Ribo Adj HR+ 2. #HorizonBreast06: ADCs in mBC 3. #TALENT: NeoAdj TDXd HR+ GI 4. #RASolute302: Panc Ca 5. #HerizonGEA01: GEJ/Gastric GU 6. #KN866: NeoAdj Pembro MIBC 7. #PEACE1: Abi in mHSPC #OncTwitter @myESMO 1/8 https://t.co/pkQxyvyRrG
4. RASolute302: Daraxonrasib vs SOC chemo in previously treated mPDAC. - mOS: 13.2 vs 6.7 mo (HR 0.40) and @FDA ✅ for all comers. - KRAS-G12D with most activity (HR: 0.48) - Benefit across RAS G12 subgroups; FDA-approved 5/8 https://t.co/nSzutOTzLj https://t.co/aiWfJZqrjY
One pager/summary of RASolute-302 trial that we touched on with #BrianWolpin from @DanaFarber after #ASCO26 plenary discussion! This study led to the approval of Daraxonrasib in 2L Pancreatic adenocarcinoma. @OncUpdates #MedX #gism https://t.co/Dmp2ihDG7X https://t.co/CbaWCaGGs4
Oncology Brothers on PROTEUS
Day 2 #ESMO26 Highlights: 1. CheckMate8HW: Nivo+Ipi in mCRC Breast Ca 2. postMONARCH: Abema+Fulv HR+ 3. VIKTORIA-1: Gedatolisib HR+ 4. TROPION-Breast02: DatoDXd TNBC GU/Gyn 5. PROTEUS: Periop Apa+ADT in Prostate Cancer #OncTwitter #bcsm #gusm #gism @myESMO 1/10 https://t.co/OR4vj1ZJUM
3. DASL-HiCaP: PhIII, Darolutamide + ADT + RT in very high-risk PCa (n=1106, incl BCR post-RP) - 4y MFS-CI 95% vs 88% (HR 0.42) - OS immature - ARPIs will play a bigger role in early prostate cancer (DASL-HiCaP & PROTEUS) 4/5 https://t.co/wEFefXA02T https://t.co/0rLGbfIjH7
5. PROTEUS: Periop Apalutamide + ADT + RP+PLND vs RP+PLND alone in high-risk localized/locally advanced Prostate Cancer: - EFS 3yr 63% vs 41% (HR 0.38) - MFS HR 0.49 - TT subsequent Rx HR 0.29. - OS immature - DASL-HiCaP also presented today. 7/10 https://t.co/cH0Skdwkwz https://t.co/ZpqdLRXoTl
Oncology Brothers on ASCENT03
Sacituzumab Govitecan ± Pembro is now @US_FDA ✅ in 1L metastatic TNBC off #ASCENT03/04! We 🗣️ these trials, findings, and AEs w/ @stolaney1 Full 🗣️: ⭐️ https://t.co/uHH1foTNZ3 ⭐️Also on “Oncology Brothers” podcast @OncUpdates #bcsm #OncTwitter https://t.co/7XVV18oCDz
Sacituzumab ± Pembro now @US_FDA ✅ in 1L mTNBC based off ASCENT03 & ASCENT04: - mPFS 9.7 vs 6.9 mos (HR: 0.62) in PDL1-ve - mPFS 11.2 vs 7.8 mos (HR: 0.65) in PDL1+ve - ⬆️ORR w/ Saci - ⬆️ diarrhea & neutropenia w/ Saci #bcsm #OncTwitter #MedX @OncUpdates @stolaney1 👏👏 https://t.co/hcr51FJRDQ
Day 3 & 4 #ASCO26 highlights: 1. #evERA: Giredestrant in mHR+ BC 2. #ASCENT03/04: Saci 1L mTNBC 3. #CIRCULATE: ctDNA in CRC 4. #EPISODE3: Adj Aspirin in CRC 5. #EMERALD3: STRIDE + TACE + Len in HCC 6. #DeLLphi304: Tarla in SCLC @ASCO #OncTwitter @OncoAlert 1/7 https://t.co/dgVSQUFdpl
Oncology Brothers on VOLGA
Day 2 (Presidential) #ESMO26 1. INTerpath001: mRNA vaccine in melanoma 2. VOLGA: Durva+EV in MIBC 3. DASLHiCaP: Dara+ADT+RT in Prost Ca 4. DeLLphi305: Tarla+Durva ES-SCLC #OncTwitter @myESMO #gusm #lcsm @OncoAlert @OncUpdates @DanaFarber @sands_jacob @tompowles1 1/5 https://t.co/Yu3s24fNTY https://t.co/yT1CxCZCYI
IO + EV upfront is now the SoC for MIBC!! But how much EV do we need in postOP settings? Eagerly looking forward to more data/discussion on Day 2 #ESMO26! VOLGA as the new SoC!!??!! #gusm @myESMO #BladderCancer https://t.co/vuu0mlgkY7 https://t.co/TQSEm2YESX
2. VOLGA: PhIII, PeriOp Durva ± Treme + NeoAdj EV vs control in cis-ineligible/refusing MIBC: - Durva + EV: 2yr EFS 64% vs 45% (HR 0.51) - 2yr OS 78% vs 69% (HR 0.58) - pCR 45% vs 10%. New SoC - G3/4 AEs 30% (D+EV), 42% (+Treme) 3/5 https://t.co/iCGItlnC9U https://t.co/l1KTOMQ8OT
Oncology Brothers on TALAPRO-3
Talazoparib now @FDA ✅ based off TALAPRO-3: Enzalutamide + Talazoparib vs. Enza alone in HRR mutated mCSPC: - At 3yrs, rPFS: 76.6% vs. 56.2% (HR: 0.48) - rPFS in BRCAm: 77.2% vs. 48.8% (HR: 0.37) - rPFS in nonBRCA: 76.2% vs. 60.2% (HR: 0.57) #OncTwitter #gusm #ProstateCancer https://t.co/RBNfJVW1iN
Day 2 #ASCO26 highlights: Breast Cancer: 1. #KN522 (update): IO + Chemo TNBC 2. #OPTIMA: Adj Chemo HR+ 3. #lidERA: Adj SERD HR+ 4. #SENOMAC: ALND omission Prostate Ca 5. #TALAPRO3: PARPi NSCLC: 6. #TRITON: Dual ICI mNSCLC #OncTwitter @ASCO @OncoAlert 1/7 https://t.co/Vl5adT0dNm
5. TALAPRO-3: PhIII, Enzalutamide + Talazoparib vs. Enza alone in HRR mutated mCSPC: - At 3yrs, rPFS: 76.6% vs. 56.2% (HR: 0.48) - rPFS in BRCAm: 77.2% vs. 48.8% (HR: 0.37) - rPFS in non-BRCA: 76.2% vs. 60.2% (HR: 0.57) - Germline and somatic testing is critical upfront! 6/7 https://t.co/pbFjPfK0nd https://t.co/QGKdmzJxNy
Oncology Brothers on CLARITY-Gastric01 (CG-01)
Day 3 (Presidential II) #ESMO26 highlights: 1. Krascendo-1: Divarasib in KRAS G12C NSCLC 2. SAFFRON: Osi + Savolitinib in EGFRm/MET+ NSCLC 3. CLARITY-Gastric01: Sone-Ve CLDN18.2 ADC in Gastric 4. HARMONi-GI1: Ivo + Chemo in 1L BTC 1/5 #OncTwitter #lcsm #gism @myESMO https://t.co/HCh0uT89j7
3. CLARITY-Gastric01: PhIII Sonesitatug vedotin (CLDN18.2 ADC) vs Chemo in 2L+ CLDN18.2+ Gastric/GEJ - 3L+ mOS 10.0 vs 5.0mos (HR 0.47) - 2L+ mOS 10.6 vs 6.4 mos (HR 0.58) - PFS not significant 🤔 - ADC activity even at lower CLDN18.2 expression 4/5 https://t.co/hNFhJsi6M6 https://t.co/dRhWgUE9cA
2 wks to #ESMO26! Here’s a📝of🔑studies for GeneralOnc that could change/reinforce SoC: - #INTerpath001 - #VOLGA - #ANZUP1801 - #LITESPARK011 - #DeLLphi305 - #SAFFRON - #CLARITYGastric01 - #MOIO - #TroFuse005 - Breast Ca Updates #OncTwitter @myESMO @OncoAlert https://t.co/9uGw605Q0W
Oncology Brothers on SAFFRON
Day 3 (Presidential II) #ESMO26 highlights: 1. Krascendo-1: Divarasib in KRAS G12C NSCLC 2. SAFFRON: Osi + Savolitinib in EGFRm/MET+ NSCLC 3. CLARITY-Gastric01: Sone-Ve CLDN18.2 ADC in Gastric 4. HARMONi-GI1: Ivo + Chemo in 1L BTC 1/5 #OncTwitter #lcsm #gism @myESMO https://t.co/HCh0uT89j7
2. SAFFRON: PhIII Osimertinib + savolitinib vs plat-pem in EGFRm/MET-high NSCLC post-osi (n=338): - mPFS 7.6 vs 5.4mos (HR 0.55) - mOS 17.8 vs 12.9mos (HR 0.68) - All-oral, OS benefit in MET-driven resistance after Osi. 3/5 https://t.co/Ei5hi7Ma1F https://t.co/icpX7OvjgA
2 wks to #ESMO26! Here’s a📝of🔑studies for GeneralOnc that could change/reinforce SoC: - #INTerpath001 - #VOLGA - #ANZUP1801 - #LITESPARK011 - #DeLLphi305 - #SAFFRON - #CLARITYGastric01 - #MOIO - #TroFuse005 - Breast Ca Updates #OncTwitter @myESMO @OncoAlert https://t.co/9uGw605Q0W
Oncology Brothers’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
We are all done with #ESMO26! 10+ studies that were on our radar and the updated data around them. Out in the community settings, it’s tough to keep up with all that is happening here in the world of cancer (and this was just ONE conference). Really appreciate you all sharing the data and importantly your take around this: @OncoAlert @weoncologists @DrChoueiri @StephenVLiu @SuyogCancer @dr_yakupergun @drsarahsam @PTarantinoMD @GIMedOnc @BijoyTelivala @RenoHemonc @nlindenberg @jryckman3 @ErikaHamilton9 @myESMO @LorenzaRimassa 🙏🏽🙏🏽
This is the treatment algorithm we’ve used during our discussion with @smitha42 for Colon/Colorectal Cancer! ✅ Early disease ✅ Biomarker & NGS driven approach ✅ Metastatic disease #OncTwitter #MedX @OncUpdates #gism https://t.co/s2QKsU6tYi https://t.co/VMDkhMHzTK
This is the treatment algorithm we’ve used during our discussion with @DrShubhamPant on #PancreaticCancer ✅ Early disease ✅ Rx in metastatic disease ⭐ But soon this would look a little different 🙏🙏 #OncTwitter #MedX @OncUpdates @OncoAlert #gism https://t.co/4Bayfle4oO https://t.co/cHCpzhCDgs
#ASCO26 is just a few days away! At 📍Marriott Marquis, May 30, 6:30-9PM, let’s discuss the current SoC & practice changing/reinforcing data! ✅ Register for this satellite event 👇 #AdvInOnc26 #OncTwitter #bcsm #lcsm #gism #gusm #MedTwitter @CathyEngMD @GIcancerDoc https://t.co/IaccqVoywx
See you tonight (Saturday, May 30) at Marriott Marquis! Let’s talk through these recent approvals and data from #ASCO26 ⭐️ 6:30-9PM CT ⭐️ Register: https://t.co/wrBIlCOV6U #AdvInOnc26 #OncTwitter #bcsm #lcsm #gism #gusm #MedTwitter @CathyEngMD @GIcancerDoc https://t.co/mfFFYlrgj8
Industry Payments
CMS Open Payments · 2025 general payments
$12,280 across 59 payments